Secondary Prevention

EAT‑Lancet Diet and Recurrent Cardiovascular Events: Lower Stroke Risk and a Signal for Myocardial Infarction in Patients with Established CVD

By MedXY 12/03/2025

Two cohort analyses suggest greater adherence to the EAT‑Lancet diet is linked with lower recurrent non‑fatal vascular events—notably stroke—and that education and sex modify long‑term cardioprotective benefits of this sustainable, plant‑forward pattern.

Cardiology news

High Lipoprotein(a) Predicts Recurrent ASCVD — Intensified LDL‑Lowering, Especially PCSK9 Inhibitors, May Attenuate Risk

By MedXY 12/02/2025

In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most notably PCSK9 inhibitors.

Cardiology news

Clopidogrel versus Aspirin for Secondary Prevention in Coronary Artery Disease: A Comprehensive Meta-Analysis

By MedXY 10/11/2025

This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.

Cardiology Clinical Updates news Specialties

Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses

By MedXY 09/02/2025

Recent evidence challenges the routine use of long-term beta-blockers after myocardial infarction in patients with preserved ejection fraction, highlighting comparable outcomes with or without therapy and raising safety and efficacy considerations in contemporary practice.

Cardiology news Specialties

Clopidogrel Surpasses Aspirin: Comprehensive Meta-Analysis Shows Superior Secondary Prevention in Coronary Artery Disease

By MedXY 09/02/2025

A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.